Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew Zhu (1) , Yoon-Koo Kang (2) , Chia-Jui Yen (3) , Richard Finn (4) , Peter Galle (5) , Josep Llovet (6, 7) , Eric Assenat (8) , Giovanni Brandi (9) , Marc Pracht (10) , Ho Yeong Lim (11) , Kun-Ming Rau (12) , Kenta Motomura (13) , Izumi Ohno (14) , Philippe Merle (15) , Bruno Daniele (16, 17) , Dong Bok Shin (18) , Guido Gerken (19) , Christophe Borg (20) , Jean-Baptiste Hiriart (21) , Takuji Okusaka (22) , Manabu Morimoto (23) , Yanzhi Hsu (24) , Paolo Abada (24) , Masatoshi Kudo (25)

1 HMS - Harvard Medical School [Boston]
2 Asan Medical Center [Seoul]
3 NCKU - National Cheng Kung University
4 David Geffen School of Medicine [Los Angeles]
5 University Medical Center [Mainz]
6 MSSM - Icahn School of Medicine at Mount Sinai [New York]
7 IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer
8 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
9 UNIBO - Alma Mater Studiorum Università di Bologna = University of Bologna
10 CRLCC - CRLCC Eugène Marquis
11 SKKU - Sungkyunkwan University [Suwon]
12 CGMH - Chang Gung Memorial Hospital [Taipei]
13 Fukuoka University
14 University of Tokyo [Kashiwa Campus]
15 Hôpital de la Croix-Rousse [CHU - HCL]
16 G Rummo Hospital
17 Ospedale del Mare
18 Gachon University Gil Medical Center [Incheon, Republic of Korea]
19 Universität Duisburg-Essen = University of Duisburg-Essen [Essen]
20 RIGHT - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)
21 Hôpital Haut-Lévêque [CHU Bordeaux]
22 Tokyo Medical University
23 Yokohama University School of Medecine
24 Eli Lilly and Company [Indianapolis]
25 Kindai University

Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher.

Domaines: Cancer

Andrew Zhu, Yoon-Koo Kang, Chia-Jui Yen, Richard Finn, Peter Galle, et al.. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, 2019, 20 (2), pp.282-296. ⟨10.1016/S1470-2045(18)30937-9⟩. ⟨hal-02927464⟩